Therapeutic Modulation of T Cells for Autoimmune Diseases

Moderator(s)

• DK

  Dimitry Krementsov

  Univ. of Vermont

Presentations:

• 12:45 PM - 1:00 PM US ET

  Site-Selective Proximity-Synthetic Editors Rewrite p53 Acetylation to Dynamically Control Treg Lineage Differentiation
  

  Author: Francisco F. Gonzalez, PhD (he/him/his) – Icahn School of Medicine, Mount Sinai
• 1:00 PM - 1:15 PM US ET

  GNTI-932: A Targeted, Scalable, and Hypoimmune Allogeneic Engineered Treg therapy for the treatment of Inflammatory Bowel Disease.
  

  Author: Martina Sassone-Corsi, PhD – GentiBio
• 1:15 PM - 1:30 PM US ET

  Engineered Nanobodies to Direct and Visualize Durable Tolerance
  

  Author: Novalia Pishesha, PhD – Boston Children's Hosp., Harvard Med. Sch.
• 1:30 PM - 1:45 PM US ET

  First Oral Small-molecule Inhibitors Designed by Generative AI Achieve Biologics-Like Pan-Inhibition of IL-17AA, AF, and FF Dimers
  

  Author: Chris Li, PhD – ByteDance AI Drug Discovery / Anew Therapeutics
• 1:45 PM - 2:00 PM US ET

  Antigen-specific depletion of gluten-reactive T cells for the potential treatment of celiac disease
  

  Author: Kaitlin A. Read, PhD – University of Pennsylvania
• 2:00 PM - 2:15 PM US ET

  UVB Phototherapy Induces a Stress-Driven Anergy Pathway as a Novel Axis of T Cell Regulation
  

  Author: Avishai maliah, MD PHD – Tel Aviv Univ. Sackler Fac. of Med.